摘要
肝衰竭是临床最常见的严重肝病临床症候群,进展快,病死率高。在肝衰竭发生前期或“黄金窗口期”进行早期干预对于改善患者预后具有重要意义。关于肝衰竭前期的研究主要集中于HBV相关慢加急性肝衰竭或酒精相关慢加急性肝衰竭。现就目前肝衰竭前期的发生机制及人工肝治疗展开讨论,旨在指导临床更加合理、有效地应用人工肝技术,推动相关研究,从而降低肝衰竭患者的病死率。
Liver failure is a common clinical syndrome of severe liver disease with rapid progression and high mortality.Therefore,early intervention in pre-liver failure or“golden window”is of great significance in improving the prognosis of patients.Hepatitis B virus-related acute-on-chronic liver failure and alcohol-related acute-on-chronic liver failure are the main topics of studies on preliver failure.This article discusses the pathogenesis of pre-liver failure and artificial liver support therapy,so as to guide the reasonable and affective applications of artificial liver technology in clinical practice,promote related studies,and thereby reduce the mortality rate of patients with liver failure.
作者
张静
周新民
ZHANG Jing;ZHOU Xinmin(Department of Gastroenterology,Xijing Hospital,Air Force Medical University,Xi’an 710032,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2024年第2期229-232,共4页
Journal of Clinical Hepatology
关键词
肝功能衰竭
肝
人工
二级预防
Liver Failure
Liver,Artificial
Secondary Prevention
